Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Japan Exchange  >  Teijin Limited    3401   JP3544000007

TEIJIN LIMITED

(3401)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

TEIJIN : Febuxostat (FEBURIC(R)) Launches in Korea(Teijin Pharma)

07/28/2011 | 02:11am EDT

Tokyo, Japan, July 28, 2011 ---Teijin Pharma Limited, the core company of the Teijin Group's medical and pharmaceutical business, announced today the launch of febuxostat, a novel drug developed by Teijin Pharma for the treatment of hyperuricemia and gout, in Korea on July 18. SK Chemicals Co., Ltd., the febuxostat licensee in Korea, is marketing the product under the brand name FEBURIC.

Teijin Pharma signed an exclusive licensing agreement with SK Chemicals in July 2004 for the development and marketing of febuxostat in Korea. In June 2009, SK Chemicals received approval from the Korea Food and Drug Administration to market the drug in the country for treatment of chronic hyperuricemia in patients with gout.

Febuxostat already is marketed by licensees, Takeda Pharmaceuticals North America, Inc. and Takeda Canada, Inc. under the brand name ULORIC in the U.S. and Canada, respectively, and marketed by Menarini Group under the brand name ADENURIC in Europe including France, the U.K., Germany, Ireland, Italy, Greece, Austria, Spain and Cyprus. In May of this year, Teijin Pharma launched the drug in Japan under the brand name FEBURIC. Collaborative efforts with licensees in other markets such as China, Hong Kong, Taiwan, Mexico, the Caribbean and Middle East and North African (MENA) regions are aimed at launching the drug in these markets as well.

Discovered by Teijin Pharma in 1991, febuxostat is the world's first non-purine selective inhibitor of xanthine oxidase. It has a novel chemical structure completely different from that of allopurinol, which has been used for over 40 years as the standard treatment for hyperuricemia and gout. Febuxostat effectively lowers the level of uric acid in the blood of hyperuricemic patients to the recommended level, and is well tolerated without need for dose adjustment in patients suffering from mild to moderate renal impairment.

Teijin Pharma has positioned febuxostat as a global strategic product and expects to achieve global annual sales of over 100 billion yen for the drug in the foreseeable future.

About Teijin Pharma Limited

Teijin Pharma Limited, the core company of Teijin Group's medical and pharmaceuticals business, focuses on three key therapeutic areas: respiratory, bone/joint, and cardiovascular/metabolic diseases. Teijin Pharma has strong marketing positions, particularly in the respiratory and bone/joint areas, with pharmaceutical products as well as a home healthcare business, including home oxygen therapy. Teijin Pharma continues to enhance its presence worldwide through in-house R&D as well as in-licensing and out-licensing activities. www.teijin-pharma.co.jp/english/index.html

About the Teijin Group

Based in Tokyo and Osaka, Japan, Teijin is a global technology-driven group operating in eight main fields: aramid fibers, carbon fibers & composites, polyester fibers, plastics, films, medical & pharmaceuticals, fiber products marketing and IT businesses. Teijin Limited, the holding company for the Teijin Group, is listed on the Tokyo and Osaka stock exchanges. The group, comprising 150 companies and 17,542 employees worldwide, had consolidated sales of JPY 815.7 billion (USD 10.1 billion) and total assets of JPY 761.5 billion (USD 9.5 billion) in the fiscal year ending March 31, 2011.

For further information, please contact:

Public Relations & Investor Relations Office

Teijin Limited

Tel: +81-3-3506-4055 / Fax: +81-3-3506-4150

E-mail: pr@teijin.co.jp


© Publicnow 2011
All news about TEIJIN LIMITED
03/31TEIJIN  : Notice Regarding Completion of Transfer of Japan Sales of Type 2 Diabe..
PU
03/30TEIJIN LIMITED : Ex-dividend day for final dividend
FA
03/23TEIJIN  : to Commence Manufacture and Sale in Japan of Abaloparatide Acetate as ..
AQ
03/16TEIJIN  : Prices Stock Acquisition Rights to Be Issued to Executives
MT
03/15TEIJIN  : Notice Regarding Determination of the Issue Price for Stock Acquisitio..
PU
03/03NOTICE REGARDING RESULT OF TENDER OF : 7774)
PU
03/01TAKEDA PHARMACEUTICAL  : to Divest Four Diabetes Products in Japan to Teijin Pha..
AQ
02/26TEIJIN  : Notice Regarding the Issuance of Stock Acquisition Rights as Stock Opt..
PU
02/26TEIJIN  : Notice of Execution of Asset Transfer Agreement for Transfer of Japan ..
PU
02/09TEIJIN  : Attributable Profit Drops 11% in April-December 2020
MT
More news
Financials
Sales 2021 806 B 7 399 M 7 399 M
Net income 2021 -9 160 M -84,1 M -84,1 M
Net Debt 2021 270 B 2 480 M 2 480 M
P/E ratio 2021 -38,1x
Yield 2021 2,88%
Capitalization 349 B 3 206 M 3 208 M
EV / Sales 2021 0,77x
EV / Sales 2022 0,83x
Nbr of Employees 20 075
Free-Float 91,7%
Chart TEIJIN LIMITED
Duration : Period :
Teijin Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TEIJIN LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 1 852,22 JPY
Last Close Price 1 820,00 JPY
Spread / Highest target 15,4%
Spread / Average Target 1,77%
Spread / Lowest Target -33,0%
EPS Revisions
Managers and Directors
NameTitle
Jun Suzuki President, CEO & Representative Director
Akihisa Nabeshima Chief Financial Officer & Representative Director
Taizo Makari Executive Officer & Head-Engineering
Fumio Ohtsubo Independent Outside Director
Yukako Uchinaga Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
TEIJIN LIMITED-6.19%3 206
XINFENGMING GROUP CO., LTD.13.17%3 333
HYOSUNG TNC CORPORATION173.46%2 198
KOLON INDUSTRIES, INC.51.04%1 564
HYOSUNG ADVANCED MATERIALS CORPORATION157.72%1 528
K.P.R. MILL LIMITED40.61%1 123